Isomorphic Labs, the DeepMind drug‑discovery spin‑off, released a technical report on IsoDDE—an AI model capable of detailed protein–drug interaction and antibody structure predictions—and kept the system proprietary. The company touted improved predictive capacities; external scientists compared the advance to a hypothetical 'AlphaFold 4' but criticized the lack of open technical detail. Researchers said IsoDDE’s performance impressed the field but lamented that the closed release prevents reproducibility and comparative development. The episode highlights tensions between corporate IP protection and the open‑science approaches that accelerated earlier structural‑prediction advances.